Indivior Pharmaceuticals (INDV) EBT Margin (2024 - 2026)

Indivior Pharmaceuticals' EBT Margin history runs 3 years deep, the most recent figure standing at 36.28% for Q1 2026.

• In Q1 2026, EBT Margin rose 1410.0% year-over-year to 36.28%; the TTM figure through Mar 2026 stood at 22.85% (up 2234.0% YoY), while the FY2025 annual figure was 19.29%, up 1761.0% from the prior year.
• EBT Margin was 36.28% for Q1 2026 at Indivior Pharmaceuticals, up from 22.63% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 36.28% in Q1 2026 to a low of 40.47% in Q2 2024.
• Historically, EBT Margin has averaged 13.46% across 3 years, with a median of 20.53% in 2025.
• Biggest YoY gain for EBT Margin was 6100 bps in 2025; the steepest drop was 352 bps in 2025.
• A 3-year view of EBT Margin shows it stood at 12.71% in 2024, then surged by 78 bps to 22.63% in 2025, then soared by 60 bps to 36.28% in 2026.
• The last three EBT Margin figures came in at 36.28% (Q1 2026), 22.63% (Q4 2025), and 11.78% (Q3 2025), per Business Quant data.